GlassScriptPhysician profile
Bronagh Senning
NPI 1336782077
$2,862.62
in general payments reported to CMS, 2019-2025
28 companies · $21.08 in 2025
The $21.08 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,209 · 2022: $1,358 · 2023: $211 · 2024: $64.84 · 2025: $21.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $296.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $457.37 | 2021-2023 | Erleada |
| Rochester Medical Corporation | $360.36 | 2022 | |
| Urovant Sciences INC | $272.58 | 2021-2022 | |
| Myovant Sciences INC. | $247.30 | 2021-2022 | |
| Astellas Pharma US INC | $229.51 | 2021-2022 | |
| Clarus Therapeutics INC. | $177.84 | 2021 | |
| Medtronic, INC. | $155.91 | 2022 | |
| Teleflex LLC | $150.43 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $130.70 | 2023-2024 | Bard Urinary Drainage Bag |
| Bayer Healthcare Pharmaceuticals INC. | $110.65 | 2021-2022 | |
| Amgen INC. | $80.65 | 2021-2022 | |
| Antares Pharma, INC. | $63.23 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $62.24 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $53.36 | 2021-2022 | |
| Boston Scientific Corporation | $52.59 | 2023-2025 | Rezum Generator, Spaceoar Vue System - 10ml |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $40.50 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $32.68 | 2023 | Aptiom |
| Pfizer INC. | $19.40 | 2022 | |
| 180 Medical, INC. | $18.78 | 2021 | |
| Argenx US, INC. | $18.77 | 2023 | |
| Blue Earth Diagnostics | $18.30 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $17.77 | 2021 | |
| Progenics Pharmaceuticals, INC. | $16.66 | 2021 | |
| Neurelis, INC. | $16.36 | 2023 | Valtoco |
| Lundbeck LLC | $15.41 | 2023 | Vyepti |
| Lilly USA, LLC | $15.09 | 2023 | Emgality |
| Myriad Genetic Laboratories, INC. | $14.09 | 2021 | |
| Abbvie INC. | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bronagh Senning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.